Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Monelle, Tamegnon"'
Autor:
G. A. Amos Burke, Luciana Vinti, Edita Kabickova, Auke Beishuizen, Nurdan Tacyildiz, Anne Uyttebroeck, Hyoung Jin Kang, Flavio Luisi, Véronique Minard-Colin, Birgit Burkhardt, Monelle Tamegnon, Steven Sun, Madeliene Curtis, Sanjay Deshpande, Kerri Nottage, Angela Howes, Srimathi Srinivasan, Deepa Bhojwani, Robin Norris, Mitchell Cairo
Publikováno v:
Blood advances, 7(4), 602-610. American Society of Hematology
Part 1 results of the open-label, randomized, global phase 3 SPARKLE trial supported continued assessment of ibrutinib with either modified rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e398afe86edb89e121a404f65bd64a1
http://www.scopus.com/inward/record.url?scp=85149128353&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85149128353&partnerID=8YFLogxK
Autor:
Amos, Burke, Luciana, Vinti, Edita, Kabickova, Auke, Beishuizen, Nurdan, Tacyildiz, Anne, Uyttebroeck, Hyoung Jin, Kang, Flavio, Luisi, Véronique, Minard-Colin, Birgit, Burkhardt, Monelle, Tamegnon, Steven, Sun, Madeliene, Curtis, Sanjay, Deshpande, Kerri, Nottage, Angela J, Howes, Srimathi, Srinivasan, Deepa, Bhojwani, Robin E, Norris, Mitchell S, Cairo
Publikováno v:
Blood advances.
Part 1 results of the open-label, randomized, global phase 3 SPARKLE trial supported continued assessment of ibrutinib with either modified rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a84e973bc0eea9f021833ccf999b0ebc
https://pubmed.ncbi.nlm.nih.gov/36541957
https://pubmed.ncbi.nlm.nih.gov/36541957
Autor:
Olga Samoilova, Marie Sarah Dilhuydy, Andre Goy, Monelle Tamegnon, Asher Chanan-Khan, Michael Hallek, Mariya Salman, Simon Rule, Kerri Nottage, Anthony R. Mato, Graeme Fraser, Natasha Schuier, Javier Loscertales, Steven Sun, Angela Howes, Sebastian Grosicki, Ann Janssens, Miguel A. Pavlovsky, Sriram Balasubramanian, Fatih Demirkan, Abraham Avigdor, Rodrigo Santucci Silva, Nancy L. Bartlett, Jiri Mayer, Anne Connor, Paula Cramer
Publikováno v:
Leukemia & Lymphoma. 61:3188-3197
We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p (n = 578) were randomized 1:1 to 420 mg daily ibrutinib or p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c046a9a5279ea635c6249892d53ddc6
https://doi.org/10.1080/10428194.2020.1795159
https://doi.org/10.1080/10428194.2020.1795159
Autor:
Christopher A, Barwacz, Gustavo, Avila-Ortiz, Veerasathpurush, Allareddy, Monelle, Tamegnon, Kaitlin, Hoogeveen
Publikováno v:
Journal (Canadian Dental Association). 82
The objective of this study was to assess the current status of Canadian predoctoral implant programs in terms of director demographics, curriculum characteristics and preferences in the techniques that are used to teach and carry out implant therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d069e2308853bef1e112cf1d0a7aed08
https://pubmed.ncbi.nlm.nih.gov/28240583
https://pubmed.ncbi.nlm.nih.gov/28240583
Autor:
Christopher A. Barwacz, Kaitlin Hoogeveen, Gustavo Avila-Ortiz, Monelle Tamegnon, Veerasathpurush Allareddy
Publikováno v:
Journal of dental education. 79(3)
The aim of this study was to provide an overview of current predoctoral implant programs in the United States, includ- ing curricular characteristics and clinical practices regarding implant therapy education and program directors' characteristics. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190c2697c4fa0e34ccaf185f8470b1b7
https://pubmed.ncbi.nlm.nih.gov/25729020
https://pubmed.ncbi.nlm.nih.gov/25729020